MAR001 Cuts Triglycerides Up to 57% Without Glycemic Trade-Off

MAR001, a novel triglyceride-lowering therapy from Marea Therapeutics, a subsidiary of Lisata Therapeutics, delivered statistically significant placebo-adjusted reductions in triglycerides ranging from 39.1% to 45.5% across all three doses at Week 12 in the Phase 2b TYDAL-TIMI 78 trial — and up to 57.2% in participants with baseline triglycerides at or above 300 mg/dL. Results were presented as a late-breaking trial at the American Heart Association 2026 Scientific Sessions and simultaneously published in The New England Journal of Medicine, two of the highest-visibility venues in cardiovascular medicine.

Clinical Findings

The TYDAL-TIMI 78 Part A data are notable on two fronts. First, the dose-response relationship held across all three arms, suggesting a tractable therapeutic window. Second, and perhaps more commercially significant for the broader cardiometabolic market, MAR001 achieved these reductions without worsening glycemic control — a clinically meaningful differentiator given that hypertriglyceridemia frequently co-presents with insulin resistance and type 2 diabetes. For formulators and ingredient developers tracking the GLP-1 and metabolic-health adjacency space, the glycemic-neutrality finding addresses a persistent concern around lipid-modifying agents in metabolically complex patients.

Market Context

Elevated triglycerides affect an estimated one-third of U.S. adults, and the intersection of dyslipidemia, metabolic syndrome, and weight management has become one of the most crowded — and competitive — segments in both pharmaceutical and functional nutrition. Ingredient suppliers have moved aggressively into this space with omega-3 concentrates, berberine standardized extracts, and plant sterol esters, all positioning against the same cardiovascular risk markers MAR001 targets. A Phase 2b readout of this magnitude, published in NEJM and presented at AHA, shifts the evidentiary benchmark and will likely pressure the broader nutraceutical category to sharpen its own clinical substantiation. Operators building heart-health and lipid-management formulations should monitor this data closely as the standard of evidence in the triglyceride-reduction claim space rises.

What Comes Next

Part A meeting all objectives positions the program for Part B enrollment and, eventually, a larger outcomes trial. For the functional foods and supplement industry, the near-term relevance is less about MAR001 itself and more about the clinical bar it establishes. Brands making structure-function claims around triglyceride support — whether via fish oil, niacin derivatives, or botanical blends — will face increasingly sophisticated retail buyers and healthcare practitioners who now have a 57.2% reduction endpoint as a reference. Companies with omega-3 and cardiometabolic ingredient portfolios should treat this publication as a signal to audit their own clinical dossiers and tighten dose-response language in their marketing materials.

Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.